Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q3 2025 (September 30)9holders −1
0new positions
1sold out
$17.11avg. 13F price*
At the end of Q3 2025, 9 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, down 1 from Q2 2025. 0 opened new positions and 1 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($8.6M), Ra Capital Management, L.P. ($5.7M) and Affinity Asset Advisors, LLC ($4.2M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $17K |
All 13F filers, Q2 2025 → Q3 2025: 4,322 shares sold, net −4,322 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $8.6M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $5.7M |
| Affinity Asset Advisors, LLC | — | No change | 245,000 | $4.2M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 100,000 | $1.7M |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $1.6M |
| Laurion Capital Management LP | — | No change | 16,666 | $285K |
| Vestcor Inc | — | No change | 9,632 | $165K |
| CIBC Private Wealth Group LLC | — | Reduce -58.3% | 1,250 | $22K |
| UBS Group AG | — | Reduce -48.4% | 512 | $9K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.